IFNß was initially used in MS because of its antiviral action but is now believed to be of benefit in MS due to its immunomodulatory properties.[14] It acts systemically to decrease T cell activation, enhance suppressor cell activity, and inhibit proinflammatory cytokines. The gene discussed is IFNA1; the disease is myeloid sarcoma.